MedTrace Logo

Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 3-year Follow-up

NCT03090503 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2019-07-10

No results posted yet for this study

Summary

This study compares the efficacy and effectiveness of two of the second-generation antipsychotics (SGAs) most used in our society in the treatment of schizophrenia (Aripiprazole and Risperidone) and the investigators do within an assistance program of early-stage psychosis individuals of the Community of Cantabria, clinical reference for the treatment of this disease in the Spanish Autonomous Community. Patients are included in a prospective naturalistic study, open flexible-doses and randomized into one of two possible patterns of treatment that includes the protocol.

Conditions

Interventions

DRUG

Aripiprazole

Initial dose: 10 mg.

DRUG

Risperidone

Initial dose: 2 mg.

Sponsors & Collaborators

  • Centro de Investigación Biomédica en Red de Salud Mental

    collaborator NETWORK

  • Instituto de Investigación Marqués de Valdecilla

    collaborator OTHER

  • Fundación Marques de Valdecilla

    lead OTHER

Principal Investigators

  • Benedicto Crespo-Facorro, Professor · University Hospital Marqués de Valdecilla, IDIVAL, Department of Psychiatry, School of Medicine, University of Cantabria, CIBERSAM Centro Investigación Biomédica en Red Salud Mental, Santander, Spain.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2019-06-30
Completion
2021-06-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03090503 on ClinicalTrials.gov